Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in
subjects with metastatic colorectal cancer who were previously randomized to best supportive
care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.